Mobile

A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006046-17

A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Disease (GERD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare efficacy (i.e. healing and symptom relief) of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg after 4-8 weeks of treatment among subjects with erosive GERD (eGERD), endoscopically confirmed to be Los Angeles (LA) grades C and D at baseline.

Critère d'inclusion

  • Erosive gastro-oesophageal reflux disease

Liens